

# Present Knowledge on the Etiology and Treatment of Adrenarche

Sharon E. Oberfield<sup>1</sup>, MD, Rachel H. Tao<sup>1</sup>, BA, Selma F. Witchel<sup>2</sup>, MD

<sup>1</sup>Division of Pediatric Endocrinology, Columbia University Medical Center, New York-Presbyterian Morgan Stanley Children's Hospital, NY, USA <sup>2</sup>Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, USA

**Corresponding author: Sharon E. Oberfield, MD**, Division of Pediatric Endocrinology, CUMC - NYP Morgan Stanley Children's Hospital, 622 West 168<sup>th</sup> Street, PH 17 West, Room 307, New York, NY 10032, USA, Tel: (212) 305-6559, Fax: (212) 305-4778, E-mail: seo8@cumc.columbia.edu

## Abstract

**P**remature adrenarche (PA) has been assumed to be a benign variant of normal pubertal development. Yet, current collective information suggests associations between PA and potential risks for development of polycystic ovary syndrome and adult diseases such as the metabolic syndrome. Adrenarche refers to the increased secretion of the adrenal androgen precursors DHEA, DHEAS, and androstenedione, which normally occurs in children at age 6-8 years. PA may be identified clinically by early pubarche, which is defined as the development of pubic or axillary hair before 8 years in girls or 9 years in boys. This paper will consider adrenal steroidogenesis, genetic markers, neurobiological changes, skeletal maturation, and associations with adult disorders. The differential diagnosis will be reviewed because PA remains a diagnosis of exclusion. Finally, synthesis of current knowledge regarding PA, suggestions for evaluation, management, and treatment are offered.

Ref: *Ped. Endocrinol. Rev.* 2018;15(3):244-254

doi: 10.17458/per.vol15.2018.otw.etiologytreatmentadrenarche

**Key words:** Adrenarche, Pubarche, Adrenal androgens, Metabolic syndrome, PCOS, Neuroendocrine

**Abbreviations:** CYP11A1 (Cytochrome P450 Family 11 Subfamily A Member 1 or Cholesterol Side-Chain Cleavage Enzyme); CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1 or Steroid 17-Alpha-Hydroxylase); CYP11B1

(Cytochrome P450 Family 11 Subfamily B Member 1); CYP21A2 (Cytochrome P450 Family 21 Subfamily A Member 2); 3B-HSD (3B-Hydroxysteroid dehydrogenase); HSD17B5 (17B-Hydroxysteroid dehydrogenase 5); SRD5A (3-oxo-5a-steroid 4-dehydrogenase); 11B-HSD2 (Corticosteroid 11-B-dehydrogenase isozyme 2); AKR1C3 (Aldo-Keto Reductase Family 1 Member C3); SULT2A1 (DHEA Sulfotransferase Family 2A Member 1); POR (Cytochrome P450 oxidoreductase)

## Introduction

Adrenarche, beginning between 6-8 years of age, is a process unique to humans and higher primates (1). Pubarche is the physical manifestation of adrenarche. Pubarche is defined as the appearance of pubic or axillary hair, which is often accompanied by adult apocrine odor, increased oiliness of the skin and hair, and acne (2). In the National Health and Nutrition Examination Survey (NHANES), the mean ages for pubic hair development were 9.5 years for non-Hispanic black girls, 10.3 years for Mexican-American girls, and 10.5 years for non-Hispanic white girls (3). For boys, mean ages for pubic hair development were 11.1 years for non-Hispanic blacks, 12.3 years for Mexican-Americans, and 12.0 years for non-Hispanic whites (3). Adrenarche reflects a change in adrenal

steroidogenesis with increased secretion of C19 steroids, predominantly dehydroepiandrosterone sulfate (DHEAS) and DHEA, from the zona reticularis (4). Adrenarche and pubarche can occur in individuals with gonadal dysgenesis and hypothalamic hypogonadism indicating that adrenarche occurs independently of gonadarche (5).

This review will summarize recent developments in the study of premature adrenarche (PA) including adrenal steroidogenesis, differential diagnosis, genetic associations, establishment of the clinical diagnosis, and the potential co-morbidities of polycystic ovary syndrome (PCOS) and the metabolic syndrome. Approaches to diagnosis and management of PA are offered.


## Adrenal Steroidogenesis

The adrenal cortex is comprised of three distinct zones. The outer zone, the zona glomerulosa (ZG), synthesizes mineralocorticoids (4). The middle zone, the zona fasciculata (ZF), secretes glucocorticoids (4). The inner zone, the zona reticularis (ZR), secretes C19 steroids especially DHEA and DHEAS (4). The proteins required for DHEAS synthesis include steroidogenic acute regulatory protein (StAR), cytochrome P450 cholesterol side chain cleavage (P450<sub>sc</sub>), 17 $\alpha$ -hydroxylase/17,20 lyase (P450<sub>c17</sub>), cytochrome P450 oxidoreductase (P450<sub>oxo</sub>), cytochrome b<sub>5</sub>, and DHEA sulfotransferase 2A1 (4) (figure 1).

Cholesterol serves as the substrate for adrenal steroidogenesis (4,6). The enzyme, 17 $\alpha$ -hydroxylase/17,20-lyase (P450<sub>c17</sub>), encoded by the 17 $\alpha$ -hydroxylase/17,20 lyase (CYP17A1) gene, serves as the “gatekeeper” of adrenal steroidogenesis. This microsomal enzyme, which is expressed in the adrenal cortex and the gonads, has two distinct activities: 1. 17 $\alpha$ -hydroxylase and 2. 17,20-lyase (7). This enzyme is not expressed in the zona glomerulosa resulting in the conversion of pregnenolone to mineralocorticoids (4). In the zona fasciculata, the 17 $\alpha$ -hydroxylase activity predominates resulting in glucocorticoid synthesis (4). In the zona reticularis, allosteric interactions with cytochrome b<sub>5</sub> favor the 17,20-lyase activity and production of C19 steroids (8-10).

DHEA sulfotransferase 2A1 (SULT2A1) is highly expressed in the zona reticularis, where it can sulfate pregnenolone, 17 $\alpha$ -hydroxypregnenolone, and DHEA to their respective sulfated products (4). Following sulfation, pregnenolone-sulfate, 17 $\alpha$ -hydroxypregnenolone-sulfate, and DHEAS cannot serve as substrates for P450<sub>c17</sub> or 3-beta hydroxysteroid dehydrogenase type 2 (3 $\beta$ HSD type 2). In addition, they cannot act as agonists at steroid hormone receptors (4). It is assumed that this metabolic pathway optimizes the flux of the  $\Delta$ 5 pathway from pregnenolone to DHEAS (11).

Investigations using liquid chromatography-tandem mass spectroscopy (LC-MS/MS) and gas chromatography-mass spectroscopy (GC-MS) have revealed that the steroid



**Figure 1. Pathway of adrenal steroidogenesis**

Blue boxes and arrows show DHEAS pathway, green show cortisol pathway, red show active adrenal androgen pathway, and purple show 11-oxC19 pathway.

hormone repertoire of the adrenal cortex is broader than traditionally recognized. Additional C19 steroids include 11-ketoandrostenedione (11ketoA4), 11 $\beta$ -hydroxyandrostenedione (11OHA4), 11 $\beta$ -hydroxytestosterone (11OHT), and 11-ketotestosterone (11ketoT) (8,9). The enzyme cytochrome P450 11 $\beta$  hydroxylase (P450 11 $\beta$  type 1) encoded by *CYP11B1* participates in the synthesis of these 11oxC19 steroids (8). Studies of adrenal vein samples have demonstrated that 11 $\beta$ -hydroxyandrostenedione is the most abundant unconjugated C19 adrenal steroid product; ACTH stimulation can enhance its production (12). Although the adrenal cortex can synthesize 11-ketoandrostenedione and 11-ketotestosterone, peripheral enzymes such as 11 $\beta$ -hydroxysteroid dehydrogenase type 2 (HSD11B2) and aldo-keto reductase 1C3 (AKR1C3/17 $\beta$ -hydroxysteroid dehydrogenase type 5) are responsible for the conversion of 11 $\beta$ -hydroxyandrostenedione to these other steroids (4). Subsequently, 11-ketotestosterone can be converted to 11-ketodihydrotestosterone (11KDHT) by peripheral 5 $\alpha$ -reductase activity (8,9) (figure 1).

Androstenedione, DHEA, and DHEAS do not display significant agonist activity at the human androgen receptor (4). These steroids require additional conversion for biologic activity at the androgen or estrogen receptor. In contrast, 11-ketotestosterone and 11-ketodihydrotestosterone are potent agonists of the androgen receptor (12,13). The other 11oxC19 steroids, 11 $\beta$ -hydroxytestosterone, 11-ketoandrostenedione, and 11 $\beta$ -hydroxyandrostenedione are less potent androgens than 11KT and 11KDHT, but all have demonstrated androgen activity in *in vitro* studies (13-15). Preliminary data suggest that the 11oxC19 steroids may play a biologically significant role in the clinical signs associated with adrenarche (8,16,17). The relative abundance of 11OHA4 in the adrenal gland and the potency of its derivatives, 11KT and 11KDHT, suggest that 11OHA4 is a significantly more important adrenal androgen than previously thought (18).

## HPA Axis

---

The hypothalamic-pituitary-adrenal (HPA) axis primarily regulates glucocorticoid secretion by negative feedback inhibition limiting the secretion of ACTH (4). ACTH is an agonist of the ACTH receptor (MC2R) and has both chronic and acute actions (4). Its chronic actions are to maintain the transcription and translation of adrenal steroidogenic enzymes (4). Acutely, ACTH promotes cortisol secretion. While ACTH facilitates the function of the zona glomerulosa, aldosterone secretion is primarily regulated by the renin-angiotensin system and serum potassium concentrations (19).

Whereas the feedback loops are well characterized for glucocorticoid and mineralocorticoid secretion, the existence and specific elements of a feedback loop involved in the

regulation of adrenal androgen secretion remain to be elucidated. The absence of adrenarche in patients with ACTH receptor mutations and ACTH deficiency imply at least a partial regulatory role for ACTH in adrenarche (20). Yet, the increasing DHEAS concentrations at adrenarche appear to be independent of circulating cortisol and ACTH concentrations (21). Despite attempts to identify an adrenal androgen stimulating factor, none of the proposed factors have withstood rigorous assessment (22).

In a cell culture system utilizing the NCI-H295R human adrenal cell line, cortisol was shown to increase DHEA production in association with competitive inhibition of 3 $\beta$ -hydroxysteroid dehydrogenase type 2 activity (11). In a different experimental paradigm using solubilized and liposome-bound preparations of purified human 3 $\beta$ HSD2, androstenedione was found to inhibit purified 3 $\beta$ -hydroxysteroid dehydrogenase type 2 activity (23). Whether these findings are applicable to the normal regulation of the human zona reticularis remains to be determined.

## Adrenarche

---

During fetal life, the fetal adrenal cortex produces DHEAS and DHEA, which provide the substrates for placental estrogen biosynthesis (4). Following birth, the involution of the fetal adrenal cortex is accompanied by a decline in DHEA and DHEAS concentrations (4,24). Adrenarche is characterized by increased DHEA and DHEAS secretion without significant changes in ACTH and cortisol secretion (4,24). Adrenarche accompanied by increased DHEA and DHEAS secretion is associated with morphological changes in the zona reticularis (24-26). These changes include increased expression of cytochrome  $b_5$  and DHEA sulfotransferase 2A1 whereas the expression of 3 $\beta$ -hydroxysteroid dehydrogenase type 2 decreases (27,28). Although adrenarche has traditionally been considered to begin only in late childhood, urinary steroid excretion indicates increased urinary androgen metabolites reflecting adrenal C19 steroid synthesis begins much earlier than 6 years of age (29). Indeed, adrenarche may represent a gradual process originating in early childhood (30).

During adrenarche, DHEAS concentrations rise to reach their peak during the second decade of life followed by a gradual decline (31). DHEAS has the highest concentration of all circulating steroid hormones (12), has a longer half-life, and shows minimal diurnal variation (32). Yet, the function(s) of DHEA and DHEAS remain unclear. These substances do not bind to the androgen receptor, but may serve as precursors for other sex steroids including estrogen, testosterone, 11 $\beta$ -hydroxyandrostenedione, and 11 $\beta$ -hydroxytestosterone (8,9).

Using normal adrenal glands obtained from subjects of different chronologic ages, double immunofluorescence analysis showed that HSD3B2 expression was largely limited

to the ZG and ZF and did not change with increasing age (33). The expression of P450c17 increased in the ZF and ZR around 5 years of age while CYB5A expression markedly rose in the ZR with increasing age (33). *CYB5A* is the gene that codes for cytochrome b<sub>5</sub>, a strong modulator of 17,20-lyase activity. These data verify that increasing *CYB5A* expression in the zona reticularis is associated with increased 17,20-lyase activity and the onset of adrenarche (34).

The ascending DHEAS concentrations during adrenarche are paralleled by rising 5-androstenediol-3-sulfate (Adiol-S) concentrations (34). When desulfated, Adiol-S can supply precursors for production of more potent androgens such as testosterone in skin and liver (28,32). In addition to signifying the onset of adrenarche, Adiol-S may serve as a precursor for additional sex steroids through peripheral tissue conversion (34).

## Differential Diagnosis of Premature Pubarche

---

Based on the mean ages of pubarche in girls and boys, premature pubarche is defined as appearance of pubic or axillary hair earlier than 8 years of age in girls and 9 years in boys (3). The differential diagnosis for premature pubarche includes PA, mild or non-classical congenital adrenal hyperplasia, androgen secreting tumors, rare genetic disorders, and exogenous androgen exposure. Gonadotropin-dependent precocious puberty rarely presents with pubic hair; breast development and testicular enlargement are typically the initial manifestations. In the absence of a validated diagnostic test, PA is a diagnosis of exclusion.

The most common differential diagnosis is congenital adrenal hyperplasia (35,36). The virilizing congenital adrenal hyperplasias are a group of autosomal recessive disorders characterized by defective glucocorticoid biosynthesis leading to loss of negative feedback inhibition, increased ACTH secretion, and subsequent increased adrenal androgen secretion (37,38). The most common form is 21-hydroxylase deficiency due to mutations in the 21-hydroxylase (*CYP21A2*) gene (38). The other virilizing CAHs are 3-beta-hydroxysteroid dehydrogenase deficiency due to *HSD3B2* mutations and 11-beta hydroxylase deficiency due to *CYP11B1* mutations (39,40). All forms manifest a phenotypic spectrum reflecting the consequences of the specific mutations. The mildest phenotype is called non-classical or late onset. The prevalence of non-classical 21-hydroxylase deficiency has been estimated to be approximately 1:1000/2000 among European Caucasians and 1:100 among Ashkenazi Jews and other middle Eastern populations, with lowest rates of 21-hydroxylase deficiency among Black patients (41). In contrast, reported cases of non-classic CAH due to *CYP11B1* and *HSD3B2*

mutations are extremely rare (42). Whereas random elevated 17-hydroxyprogesterone concentrations may confirm the diagnosis of non-classical 21-hydroxylase deficiency, obtaining an elevated ACTH stimulated 17-OHP value may be necessary to confirm the diagnosis of 21-hydroxylase deficiency in some patients (35,42).

Several rare genetic disorders are associated with premature pubarche. As noted above DHEA is converted to DHEAS by the enzyme, *SULT2A1* (4). This enzyme requires a sulfate donor, PAPS (43). Loss of function mutations in the *PAPSS2* gene have been associated with premature pubarche, elevated DHEA concentrations, elevated androgens, and low DHEAS concentrations (43,44). Apparent cortisone reductase deficiency, due to loss of function mutations in the hexose-6-phosphate dehydrogenase (*H6PD*) gene, can also be associated with premature pubarche and increased DHEAS, androstenedione, and testosterone concentrations (45). The *H6PD* loss of function mutations prevent local conversion of cortisone to cortisol resulting in accelerated peripheral clearance of cortisol, decreased negative feedback inhibition of the HPA axis, and increased ACTH secretion (45).

Virilizing adrenal or gonadal tumors are rare, but can present with premature pubarche and virilization (46,47). Adrenal tumors include adrenocortical adenomas, adrenocortical carcinomas, bilateral macronodular hyperplasia, and adrenal oncocytomas (48). Expression of steroidogenic enzymes may be altered in the neoplastic tissue (49). Curiously, an androgen and desoxycorticosterone (DOC)-secreting right adrenal tumor was identified in a non-Cushingoid 14-year-old girl who presented with secondary amenorrhea, hypertension and virilization; her hormone concentrations recapitulated the findings associated with 11B-hydroxylase deficiency (50). Removal of the tumor normalized her clinical and hormone findings suggesting that the pattern of steroidogenesis provoked by the tumor mimicked a secondary inhibition of 11B-hydroxylase (50). The tempo of pubertal progression is often rapid in patients with androgen secreting tumors (47-50). Growth velocity and skeletal maturation may be accelerated (48). Tumors in the testis, brain, or liver may secrete serum B-human chorionic gonadotropin (hCG) that can stimulate testicular LH receptors to produce testosterone (51,52). Hence, boys with hCG secreting tumors may have testicular enlargement (51,52). Girls generally do not present with PA or precocious puberty due to hCG secreting tumors because in the absence of FSH estrogens are not synthesized. Ovarian sclerosing cell tumors and ovarian sex cord stromal tumors can secrete androgens and present with premature pubarche or virilization (47,53,54).

Exogenous androgen exposure from creams or gels containing testosterone, DHT or A4 can result in premature pubarche, and/or other androgenic signs (55,56). Exogenous steroids can be transferred to a patient by direct application, or via skin-

to-skin contact (55,56). In general, a thorough medical history can exclude the possibility of exogenous androgen exposure.

Central precocious puberty (CPP), also known as GnRH-dependent precocious puberty, is caused by early reactivation of the hypothalamic-pituitary-gonadal axis (57). CPP may present with pubic or axillary hair, but is clinically differentiated from PA by the presence of breast or testicular development (57). As in PA, androgens are elevated for age. Bone age and linear growth velocity are usually accelerated (58). In some instances, secondary CPP occurs associated with advanced skeletal maturation caused by virilizing tumors or untreated congenital adrenal hyperplasia (59-61).

PA is a diagnosis of exclusion. In other words, other potential etiologies need to be excluded based on medical history, clinical findings, or laboratory results (2,35,47). Typically, patients present with premature development of pubic hair, axillary hair, apocrine body odor, or acne (2,4). Characteristically, features of gonadarche are absent (2,62). Patients with PA tend to be heavier and taller than their peers (2). In a retrospective cohort, girls with PA demonstrated greater linear growth and weight gain beginning in early childhood (4,63). The age at menarche was found to be slightly earlier than expected in Finnish and Catalan girls who had presented with PA (64,65).

Laboratory data typically reveal DHEAS and DHEA concentrations consistent with the stage of pubic hair development. Decreased IGFBP1 and increased IGF-1 concentrations have been described in girls with PA (66). However, it has been documented that clinical signs of adrenarche and pubarche do not always correlate well with circulating levels of DHEA, DHEAS, or androstenedione (63,67). In these cases, prepubertal intracrine metabolism within target tissues is speculated to modulate the clinical features (68). Armengaud *et al.* proposed that an early morning basal 17-OHP concentration greater than 200 ng/dL is 100% sensitive and 99% specific for non-classical 21-hydroxylase deficiency; these data suggest that early morning 17-OHP concentrations less than 200 ng/dL would distinguish patients with PA from those with non-classical CAH (35).

### Advanced Bone Age and Height Predictions

---

PA may be accompanied by advanced skeletal maturation as assessed by bone age X-rays. If the bone age is significantly advanced, the likelihood of identifying a child with non-classical CAH is increased (69).

In some studies, patients with PA have been reported to have decreased predicted adult heights (70,71). Yet, other

studies suggest that advanced bone age has minimal effect on predicted adult heights in this patient population (64,72,73). A larger cross-sectional study showed that although advanced bone age was common in PA, the impact on predicted adult height appeared to be minor (74). One limitation is that all aforementioned cross-sectional studies lack final height data. A retrospective review of medical records indicated that 85 girls with PA achieved adult heights within their mid-parental range (75).

Though the exact etiology of the advanced bone age observed in some patients with PA remains unclear, many factors including insulin, DHEAS, IGF-1, and leptin concentrations as well as the rate of weight gain influence the tempo of bone maturation. Advanced bone ages are found in approximately 25% of obese children (76). Obesity appears to have a potentiating effect on bone age advancement in children with PA (71,77). In a cross-sectional study involving Korean children, bone age advancement was positively correlated with androstenedione and testosterone concentrations independent of BMI (78).

### Genetics

---

In a 1994 twin study, adrenal androgen excretion showed a heritability of 58% in prepubertal and pubertal subjects (79). Occasionally, premature pubarche can occur without a rise in adrenal androgens (80). In these cases, the bone age is not advanced, the growth velocity is not accelerated for age, and DHEAS concentrations are not elevated (80). It has been suggested that these individuals have increased androgen receptor sensitivity to low circulating androgen concentrations (80). Among a small number of girls (n=25), the length of the polyglutamine tract, which is composed of a variable number of CAG repeats in the androgen receptor (*AR/NR3C4*) gene, was decreased and methylation of the *AR* gene was decreased (80). These characteristics may be associated with increased androgen receptor sensitivity to androgens (80). However, no differences in CAG repeat number were found among Korean girls with premature pubarche, but the mean DHEAS concentration was higher in the premature pubarche group compared to the control group indicating that some girls likely had PA and not just premature pubarche (81).

The diallelic melanocortin-2 receptor promoter polymorphism for the ACTH receptor (*MC2R-2* T>C) has been associated with PA (82). Children with the *MC2R-2* T>C polymorphism had higher baseline ACTH, DHEA, and androstenedione levels than controls (82). Though the mechanism by which the *MC2R-2* T>C affects adrenarche remains unclear, this result points toward the potential role of ACTH and its receptor in the etiology of PA.

In both Catalan and Caucasian Oxford populations, variation at aromatase SNP\_50 has been associated with premature

pubarche and PCOS (83). Since aromatase catalyzes the conversion of androgens to estrogens, this finding may be relevant to the etiology of PA and PCOS in girls (83). Genetic variations in the aromatase gene have been suggested to contribute to androgen excess through impaired conversion of androgens to estrogens (83).

Heterozygosity for *CYP21A2* mutations has also been associated with PA in some populations (84-86). The A→G single nucleotide polymorphism in the IGF-1 receptor (*IGF1R*) gene has been associated with higher IGF-1 concentrations (87). The frequency of this SNP was increased in a small cohort of American children with PA (87). In a Finnish cohort, common polymorphisms in the *POR*, *SULT2A1*, and *HSD11B1* genes were not associated with PA (88).

## Risk for PCOS

---

Though previously considered a benign variant of normal pubertal development, PA may be associated with an increased risk to develop polycystic ovary syndrome (89-99). Studies of Catalan girls have shown a 45% incidence of PCOS in women who had previously been diagnosed with premature pubarche (89). Low birth weight followed by excessive weight gain during early childhood has been associated with PA, hyperinsulinemia, and central adiposity in some studies (93).

Several studies investigating the relationships between PA and hyperinsulinemic androgen excess have involved a cohort of Catalan girls with PA (65,72,73,83,89,93-99). Findings in this cohort have included dyslipidemia, increased visceral fat, and altered concentrations of inflammatory markers (94). In addition, first-degree relatives of these girls have a higher risk for impaired glucose tolerance, type 2 diabetes, hyperandrogenism, and gestational diabetes mellitus (95). In this cohort, hyperinsulinemia was correlated with the degree of ovarian hyperandrogenism among the girls who developed hyperinsulinemic androgen excess (96). Prenatal growth restraint such as intrauterine growth restriction followed by rapid postnatal weight gain appear to be associated with hyperinsulinemic androgen excess and risk for progression to PCOS (97). A recent paper showed that children born large for gestational age had lower DHEAS concentrations and speculated that early genetic and/or epigenetic factors modulated adrenal androgen secretion and onset of adrenarche (100).

The estimated incidence of PCOS worldwide is 6-15% (101). Women with PCOS have been found to have higher incidence of cardiovascular risk factors, including insulin resistance, hyperinsulinemia, glucose intolerance, increased abdominal adiposity, dyslipidemia, hypertension, and endothelial dysfunction (99,102). Since an association has been made between PA, adolescent hyperinsulinemic androgen

excess, and PCOS, metformin treatment has been utilized to normalize circulating insulin, IGFBP1, lipids, and leptin concentrations (99). However, long term longitudinal studies are essential to confirm these initial promising results and potentially identify which factors predict progression from PA to PCOS (103).

## Obesity, Insulin, Metabolic Syndrome and Premature Adrenarche

---

Hyperinsulinemia and/or insulin resistance are common in children with PA and may influence the relationship between PA and PCOS. Previous studies have demonstrated associations between PA, hyperinsulinemia, insulin resistance, and ovarian hyperandrogenism (66,72,104). *In vitro*, IGF-1 and insulin potentiate LH-stimulated androgen synthesis in theca-interstitial cells, suppress SHBG production in hepatoma cell lines, and induce steroidogenic enzymes in cultured human adrenocortical cells (105-107). PCOS and PA are also both associated with decreased IGFBP1 concentrations, which are inversely correlated with fasting insulin levels and ACTH-stimulated adrenal steroid levels (66). Insulin also decreases SHBG synthesis resulting in elevated circulating free androgen concentrations (108). SHBG concentrations may represent a biomarker associated with insulin resistance and increased risk for development of type 2 diabetes (109).

The molecular basis of the insulin resistance and hyperinsulinemia in PA is likely multi-factorial. Obesity generally decreases insulin sensitivity, resulting in compensatory hyperinsulinemia to maintain euglycemia (110,111). With obesity, one potential mechanism is that adipose tissue lipid storage is saturated leading to impaired insulin-suppressed lipolysis resulting in increased circulating free fatty acid concentrations and ectopic fat storage (110,111). This alteration in lipid storage can provoke a shift to a pro-inflammatory state accompanied by increased peripheral insulin resistance and metabolic dysfunction (110,111). In addition to obesity, other potential mechanisms for insulin resistance include defective post-receptor insulin signaling, increased free fatty acids (FFAs), hyperandrogenemia, and altered cytokine secretion and action (112).

The metabolic syndrome is defined as a cluster of cardio-metabolic risk factors that predict the propensity to develop type 2 diabetes and cardiovascular disease (113). Although several definitions have been delineated for metabolic syndrome in children, the presence of metabolic syndrome in children and adolescents is associated with an increased risk to develop type 2 diabetes in adulthood (114). All available definitions of the metabolic syndrome in children include components representing obesity (BMI or waist circumference), dyslipidemia (high triglycerides and low HDL cholesterol

concentrations), elevated blood pressure, and glucose metabolism (115). Using a metabolic syndrome severity score to account for significant sex- and racial/ethnic differences in these components among children, the longitudinal Princeton Lipid Cohort Study reported that higher childhood metabolic syndrome severity scores were associated with development of cardiovascular disease and type 2 diabetes (116).

Insulin resistance has been described among girls with PA. In a homogenous Catalan population, insulin resistance, dyslipidemia, increased waist circumference, and increased total fat mass were reported in girls with PA (96,99,117). Williams *et al.* also found that androgens were associated with higher triglycerides concentrations, greater waist circumference, and higher lean mass (90). However, these findings have not been uniformly corroborated by other groups (118).

In a cross-sectional study involving 30 children with PA and 28 controls, obesity appeared to be the driver of metabolic risk in children with PA because metabolic syndrome, as defined by the National Cholesterol Education Program Adult Treatment Panel III, was only seen in obese patients, whether or not they had PA (90). This association between obesity and PA informed on the relationship between PA and bone age advancement (77). Sopher *et al.* suggested the possibility of a hormone factor which exaggerates the effect of obesity on bone age maturation in children with obesity and/or PA (119). Despite comparable DHEAS concentrations, increased percent body fat and increased occurrence of clinical signs of adrenarche were more common among Finnish girls compared to Finnish boys leading to the speculation that the sexual dimorphism in the incidence of PA could reflect sex-dependent differences in peripheral androgen metabolism or action as modified by adipose tissue (120). The lack of conclusive data emphasizes the need for further study of the possible mechanism(s) linking PA, insulin sensitivity, insulin secretion, obesity, dyslipidemia, inflammation, PCOS, and the metabolic syndrome.

### Neurobiological Development

---

Puberty is characterized by changes in physical development, hormone concentrations, social experiences, and neurobiological development. The precise relationship of adrenarche and increasing DHEA and DHEAS concentrations to neurobiological development is unclear. Although adrenarche has been considered to be limited to humans and a few non-human primates, detailed investigations demonstrated increased DHEA and DHEAS secretion accompanied by morphological differentiation of the ZR occur during the first few weeks of life in rhesus monkeys (121,122). These studies suggest that adrenarche defined as increased DHEA/DHEAS secretion and morphological changes in the ZR may occur in some Old World primates, but likely during a different

developmental window (121,122). Thus, it has been suggested that this evolution in the timing of adrenarche has led to extended brain development in humans associated with synaptic pruning (123).

The changes in development and hormone concentrations during adrenarche and gonadarche may influence psychosocial development. Alternatively, environmental exposures such as nutrition and stress may modulate neurobiological maturation. A cross-sectional study showed that first generation female migrants from Bangladesh had earlier onset of adrenarche than second generation girls, native British girls, and girls still living in Sylhet, Bangladesh (124). Although attributed to improved nutrition and catch-up, the stress of the novel environment could be a factor.

Girls with both PA and lower executive functioning had higher externalizing and anxiety symptoms (125). Compared to girls with “on-time puberty”, some girls with PA have been reported to manifest more oppositional, defiant, anxiety, mood, or disruptive behavior disorders suggesting a greater vulnerability to psychopathology than “on-time” adrenarche girls (126). The existence of a developmental track that starts with prenatal stress associated with maternal depression and leading to elevated childhood cortisol concentrations, PA, and adolescent mental health issues has been postulated (127).

Findings from studies comparing DHEA/DHEAS concentrations with brain and pituitary morphology showed a positive correlation with cortical thickness in prefrontal areas and pituitary volume (128,129). In a longitudinal study involving healthy children, the structural development of specific subcortical brain regions was found to change during puberty (130). Amygdala and hippocampus volume increased across puberty whereas the volumes of other structures including the nucleus accumbens, caudate, putamen and globus pallidus decreased (130). A systemic review concluded that, in general, earlier onset of adrenarche and higher DHEA/DHEAS concentrations were associated with more mental health problems (131). Hence, adrenarche represents a sensitive period for neurobiological development.

### Evaluation and Treatment

---

Again, PA is a diagnosis of exclusion. Following diagnosis, no specific medical treatment is generally necessary. Nevertheless, regular clinical re-evaluations are recommended to assess linear growth velocity, weight gain, skeletal maturation, and progressive androgen excess. To track potential progression of androgen excess, adrenal androgen levels may be measured annually. After menarche, girls with a history of PA may be followed annually. If menstrual regularity has not been established two years post-menarche, re-evaluation for progression to PCOS may be warranted.

Annual fasting measures of insulin resistance, i.e. fasting glucose to insulin ratio (FGIR), HgbA1C, or homeostatic model assessment of insulin resistance (HOMA), and lipid levels may be helpful because of the potential to develop signs and symptoms of comorbidities such as the metabolic syndrome. If there is evidence of insulin resistance, metformin may be recommended. For irregular menses and/or hirsutism, treatment with oral contraceptive pills may be beneficial. In all cases, adherence to a low-fat, low-glycemic index diet and regular exercise is recommended to mitigate risk for comorbidities and to promote healthy skeletal growth and appropriate pubertal development. Given the potential psychological consequences of premature adrenarche and abnormal pubertal timing on children, monitoring the physical and psychological development of children with premature adrenarche will be worthwhile.

## Conclusion

The specific physiologic mechanisms instigating the onset of increased DHEA and DHEAS secretion by the zona reticularis remain to be clarified. Available data support the statement that PA is usually a benign maturational phenomenon that is a diagnosis of exclusion. Nevertheless, children with PA have a higher risk for obesity, impaired carbohydrate metabolism, dyslipidemia, advanced skeletal maturation, and psychopathology during childhood. Alterations in steroidogenesis, neuroendocrine function, insulin sensitivity, genetic factors, and environmental exposure likely influence the risk for progression from PA to PCOS.

## Disclosure

None of the authors have conflicts of interest to disclose.

## References

- Cutler GB Jr, Glenn M, Bush M, Hodgen GD, Graham CE, Loriaux DL. Adrenarche: a survey of rodents, domestic animals, and primates. *Endocrinology* 1978;103(6):2112-2118
- Utriainen P, Laasko S, Liimatta J, Jaaskelainen J, Voutilainen R. PA—a common condition with variable presentation. *Horm Res Pediatr* 2015;83(4):221-231
- Sun SS, Schubert CM, Chumlea WC, Roche AF, Kulin HE, Lee PA, Himes JH, Ryan AS. National estimates of the timing of sexual maturation and racial differences among US children. *Pediatrics* 2002;110(5):911-919
- Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. *Endocr Rev* 2011;32(1):81-151
- Sklar CA, Kaplan SL, Grumbach MM. Evidence for dissociation between adrenarche and gonadarche: studies in patients with idiopathic precocious puberty, gonadal dysgenesis, isolated gonadotropin deficiency, and constitutionally delayed growth and adolescence. *J Clin Endocrinol Metab* 1980;51(3):548-556
- Stocco DM, Clark BJ. Regulation of the acute production of steroids in steroidogenic cells. *Endocr Rev* 1996;17:221-244
- Miller WL, Auchus RJ, Geller DH. The regulation of 17,20 lyase activity. *Steroids* 1997;62(1):133-142
- Turcu AF, Auchus RJ. Clinical significance of 11-oxygenated androgens. *Curr Opin Endocrinol Diabetes Obes* 2017;24(3):252-259
- Pretorius E, Arlt W, Storbeck K. A new dawn for androgens: Novel lessons from 11-oxygenated C19 steroids. *Mol Cell Endocrinol* 2017;441:76-85
- Miller WL, Tee MK. The post-translational regulation of 17,20 lyase activity. *Mol Cell Endocrinol* 2015;408:99-106
- Topor LS, Asai M, Dunn J, Majzoub JA. Cortisol stimulates secretion of dehydroepiandrosterone in human adrenocortical cells through inhibition of 3betaHSD2. *J Clin Endocrinol Metab* 2011;96(1):E31-E39
- Rege J, Nakamura Y, Satoh F, Morimoto R, Kennedy MR, Layman LC, Honma S, Sasano H, Rainey WE. Liquid chromatography-tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation. *J Clin Endocrinol Metab* 2013;98:1182-1188
- Storbeck KH, Bloem LM, Africander D, Schloms L, Swart P, Swart AC. 11B-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer? *Mol Cell Endocrinol* 2013;377(1-2):135-146
- Akram ON, Bursil C, Desai R, Desai R, Heather AK, Kazlauskas R, Handelsman DJ, Lambert G. Evaluation of androgenic activity of nutraceutical-derived steroids using mammalian and yeast in vitro androgen bioassays. *Anal Chem* 2011;83:2065-2074
- Campana C, Rege J, Turcu AF, Pezzi V, Gomez-Sanchez CE, Robins DM, Rainey WE. Development of a novel cell based androgen screening model. *J Steroid Biochem Mol Biol* 2016;156:17-22
- Holownia P, Owen EJ, Conway GS, Round J, Honour JW. Studies to confirm the source of 11 beta-hydroxyandrostenedione. *J Steroid Biochem Mol Biol* 1992;41(3-8):875-880
- Rege J, Kasa-Vubu JZ, Muth T, Auchus RJ, Smith JM, White PC, Rainey WE. PA is marked by elevated levels of serum 11-ketotestosterone and delta5-steroid sulfates (abstract). In: *Endocrine Society Annual Meeting*. Orlando, FL April 1-4, 2017
- du Toit T, Bloem LM, Quanson JL, Ehlers R, Serafin AM, Swart AC. Profiling adrenal 11beta-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC2-MS/MS quantification of 11beta-11keto-dihydrotestosterone. *J Steroid Biochem Mol Biol* 2017;166:54-67
- Scaroni C, Opocher G, Mantero F. Renin-angiotensin-aldosterone system: a long-term follow-up study in 17alpha-hydroxylase deficiency syndrome. *Clin Exp Hypertens A* 1986;8:773-780
- Weber A, Clark AJ, Perry LA, Honour JW, Savage MO. Diminished adrenal androgen secretion in familial glucocorticoid deficiency implicates a significant role for ACTH in the induction of adrenarche. *Clin Endocrinol (Oxf)* 1997;46(4):431-437
- Kenny FM, Preeyasombat C, Migeon CJ. Cortisol production rate in normal infants, children, and adults. *Pediatrics* 1966;37:34-42
- Anderson DC. The adrenal androgen-stimulating hormone does not exist. *Lancet* 1980;2:454-456
- Thomas JL, Rajapaksha M, Mack VL, DeMars GA, Majzoub JA, Bose HS. Regulation of human 3B-hydroxysteroid dehydrogenase type 2 by adrenal corticosteroids and product-feedback by androstenedione in human adrenarche. *J Pharmacol Exp Ther* 2015;352(1):67-76
- Dhom G. The prepubertal and pubertal growth of the adrenal (adrenarche). *Beitr Pathol* 1973;150:357-377
- Belgorosky A, Baquedano MS, Guercio G, Rivarola MA. Adrenarche: postnatal adrenal zonation and hormonal and metabolic regulation. *Horm Res* 2008;70:257-267
- Bird IM. In the zone: understanding zona reticularis function and its transformation by adrenarche. *J Endocrinol* 2012;214:109-111



27. Suzuki T, Sasano H, Takeyama J, Kaneko C, Freije WA, Carr BR, Rainey WE. Developmental changes in steroidogenic enzymes in human postnatal adrenal cortex: immunohistochemical studies. *Clin Endocrinol (Oxf)* 2000;53(6):739-747
28. Hui XG, Akahira J, Suzuki T, Nio M, Nakamura Y, Suzuki H, Rainey WE, Sasano H. Development of the human adrenal zona reticularis: morphometric and immunohistochemical studies from birth to adolescence. *J Endocrinol* 2009;203(2):241-252
29. Remer T, Boye KR, Hartmann MF, Wudy SA. Urinary markers of adrenarche: reference values in healthy subjects, aged 3-18 years. *J Clin Endocrinol Metab* 2005;90(4):2015-2021
30. Palmert MR, Hayden DL, Mansfield MJ, Crigler JF Jr, Crowley WF Jr, Chandler DW, Boepple PA. The longitudinal study of adrenal maturation during gonadal suppression: evidence that adrenarche is a gradual process. *J Clin Endocrinol Metab* 2001;86(9):4536-4542
31. Rege J, Rainey WE. The steroid metabolome of adrenarche. *J Endocrinol* 2012;214:133-143
32. Longcope C. Dehydroepiandrosterone metabolism. *J Endocrinol* 1996;150:S125-S127
33. Nakamura Y, Xing Y, Hui X-G, Kurotaki Y, Ono K, Cohen T, Sasano H, Rainey WE. Human adrenal cells that express both 3beta-hydroxysteroid dehydrogenase type 2 (HSD3B2) and cytochrome b<sub>5</sub> (CYB5A) contribute to adrenal androstenedione production. *J Steroid Biochem Mol Biol* 2011;123:122-126
34. Rege J, Karashima S, Lerario AM, Smith JM, Auchus RJ, Kasa-Vubu JZ, Sasano H, Nakamura Y, White PC, Rainey WE. Age-dependent increases in adrenal cytochrome b<sub>5</sub> and serum 5-androstenediol-3-sulfate. *J Clin Endocrinol Metab* 2016;101(12):4585-4593
35. Armengaud JB, Charkaluk ML, Trivin C, Tardy V, Breart G, Brauner R, Chalumeau M. Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from PA. *J Clin Endocrinol Metab* 2009;94(8):2835-2840
36. New MI. An update of congenital adrenal hyperplasia. *Annals of the New York Academy of Sciences* 2004;1038:14-43
37. New MI, Levine LS. Congenital adrenal hyperplasia. *Clin Biochem* 1981;14(5):258-272
38. Migeon CJ, Donohoue PA. Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. Its molecular basis and its remaining therapeutic problems. *Endocrinol Metab Clin North Am* 1991;20(2):277-296
39. Pang S, Lerner AJ, Stoner E, Levine LS, Oberfield SE, Engel I, New MI. Late-onset adrenal steroid 3beta-hydroxysteroid dehydrogenase deficiency. I. A cause of hirsutism in pubertal and postpubertal women. *J Clin Endocrinol Metab* 1985;60(3):428-439
40. Fraiser SD, Horton R, Ulstrom RA. Androgen metabolism in congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. *Pediatrics* 1969;44:201-208
41. Carmina E, Dewailly D, Escobar-Morreale HF, Kelestimir F, Moran C, Oberfield S, Witchel SF, Azziz R. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. *Hum Reprod Update* 2017;5:1-20
42. Reisch N, Högl W, Parajes S, Rose IT, Dhir V, Götzinger J, Arlt W, Krone N. A diagnosis not to be missed: nonclassic steroid 11β-hydroxylase deficiency presenting with PA and hirsutism. *J Clin Endocrinol Metab* 2013;98(10):E1620-E1625
43. Noordam C, Dhir V, McNelis JC, Schlereth F, Hanley NA, Krone N, Smeitink JA, Smeets R, Sweep F, Claahsen-van der Grinten HL, Arlt W. Inactivating PAPSS2 mutations in a patient with premature pubarche. *N Engl J Med* 2009;360:2310-2318
44. Oostdijk W, Idkowiak J, Mueller JW, House PJ, Taylor AE, O'Reilly MW, Hughes BA, de Vries MC, Uitterlinden AG, Wit JM, Losekoot M, Arlt Wiebke. PAPSS2 deficiency causes androgen excess via impaired DHEA sulfation—in vitro and in vivo studies in a family harboring two novel PAPSS2 mutations. *J Clin Endocrinol Metab* 2015;100(4):E672-E680
45. Lavery GG, Idkowiak J, Sherlock M, Bujalska I, Ride JP, Saqib K, Hartmann MF, Hughs B, Wudy SA, De Schepper J, Arlt W, Krone N, Shackleton CH, Walker EA, Stewart PM. Novel H6PDH mutations in two girls with PA: 'apparent' and 'true' CRD can be differentiated by urinary steroid profiling. *Eur J Endocrinol* 2013;168(2):K19-K26
46. Subbiah S, Nahar U, Samujh R, Bhansali A. Heterosexual precocity: rare manifestation of virilizing adrenocortical oncocytoma. *Ann Saudi Med* 2013;33(3):294-197
47. Paris F, Kalfa N, Philibert P, Jeandel C, Gaspari L, Sultan C. Very premature pubarche in girls is not a pubertal variant. *Hormones* 2012;11(3):356-360
48. Michalkiewicz E, Sandrini R, Figueiredo B, Miranda EC, Caran E, Oliveira-Filho AG, Marques R, Pianovski MA, Lacerda L, Cristofani LM, Jenkins J, Rodriguez-Galindo C, Ribeiro RC. Clinical and outcome characteristics of children with adrenocortical tumours: a report from the International Pediatric Adrenocortical Tumor Registry. *J Clin Oncol* 2004;22(5):838-845
49. Tetsi Nomigni M, Ouzounian S, Benoit A, Vadrot J, Tissier F, Renouf S, Lefebvre H, Christin-Maitre S, Louiset E. Steroidogenic enzyme profile in an androgen-secreting adrenocortical oncocytoma associated with hirsutism. *Endocr Connect* 2015;4(2):117-127
50. Soranno D, Prasad V, David R, Oberfield S, Greco A, Sivaraman N, Drucker W. Hypertension and virilization caused by a unique desoxycorticosterone- and androgen-secreting adrenal adenoma. *J Pediatr Endocrinol Metab* 1999;12(2):215-220
51. Takahashi H, Tokudo N, Kariya H. Precocious puberty in a seven-year-old boy due to human chorionic gonadotropin producing pineal tumor detected by nuclear magnetic resonance computed tomography scanning. *Acta Paediatr Jpn* 1990;32(1):88-93
52. Eren E, Demirkaya M, Cacir EDP, Sevinir B, Saglam H, Tarim O. A rare cause of precocious puberty: hepatoblastoma - case report. *J Clin Res Pediatr Endocrinol* 2009;1(6):281-283
53. Yen E, Deen M, Marshall I. Youngest reported patient presenting with an androgen producing sclerosing stromal ovarian tumor. *J Pediatr Adolesc Gynecol* 2014;27(5):e121-e124
54. Fresneau B, Orbach D, Faure-Contier C, Verité C, Castex MP, Kalfa N, Martelli H, Patte C. Sex-cord stromal tumors in children and teenagers: results of the TGM-95 study. *Pediatr Blood Cancer* 2015;62(12):2114-2119
55. Martinez-Pajares JD, Diaz-Morales O, Ramos-Diaz JC, Gomez-Fernandez E. Peripheral precocious puberty due to inadvertent exposure to testosterone: case report and review of the literature. *J Pediatr Endocrinol Metab* 2012;25(9-10):1007-1012
56. Kunz GJ, Klein KO, Clemons RD, Gottschalk ME, Jones KL. Virilization of young children after topical androgen use by their parents. *Pediatrics* 2004;114(1):282-284
57. Skylar CA, Kaplan SL, Grumbach MM. Evidence for dissociation between adrenarche and gonadarche: studies in patients with idiopathic precocious puberty, gonadal dysgenesis, isolated gonadotropin deficiency, and constitutionally delayed growth and adolescence. *J Clin Endocrinol Metab* 1980;51:548-556
58. Paul D, Conte FA, Grumbach MM, Kaplan SL. Long-term effect of gonadotropin-releasing hormone against therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. *J Clin Endocrinol Metab* 1995;80:546-551
59. Pescovitz OH, Comite F, Cassorla F, Dwyer AJ, Poth MA, Sperling MA, Hench K, McNemar A, Skerda M, Loriaux DL, Cutler GB. True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone-releasing hormone analog. *J Clin Endocrinol Metab* 1984;58(5):857-861
60. Miyoshi Y, Oue T, Oowari M, Soh H, Tachibana M, Kimura S, Kiyohara Y, Yamada H, Bessyo K, Mushiake S, Homma K, Hasegawa T, Sasano H, Ozono K. A case of pediatric virilizing adrenocortical tumor resulting in hypothalamic-pituitary activation and central precocious puberty following surgical removal. *Endocr J* 2009;56(8):975-982

61. Sahana PK, Gopal Sankar KS, Sengupta N, Chattopadhyay K. Boy with central precocious puberty probably due to a peripheral cause. *BMJ Case Rep* 2016; doi: 10.1136/bcr-2016-214554
62. Silverman SH, Migeon C, Rosemberg E, Wilkins L. Precocious growth of sexual hair without other secondary sexual development: "premature pubarche," a constitutional variation of adolescence. *Pediatrics* 1952;10:426-432
63. Utriainen P, Voutilainen R, Jaaskelainen J. Continuum of phenotypes and sympathoadrenal function in PA. *Eur J Endocrinol* 2009;160:657-665
64. Pere A, Perheentupa J, Peter M, Voutilainen R. Follow up of growth and steroids in PA. *Eur J Pediatr* 1995;154(5):346-352
65. Ibáñez L, Jiménez R, de Zegher F. Early puberty-menarche after precocious pubarche: relation to prenatal growth. *Pediatrics* 2006;117(1):117-121
66. Silfen ME, Manibo AM, Ferin M, McMahon DJ, Levine LS, Oberfield SE. Elevated free IGF-I levels in prepubertal Hispanic girls with PA: relationship with hyperandrogenism and insulin sensitivity. *J Clin Endocrinol Metab* 2002;87(1):398-403
67. Patterson WF, Ahmed SF, Bath I, Donaldson MDC, Fleming R, Greene SA, Hunter I, Kelnar CJH, Mayo A, Schulga JS, Shapiro D, Smail PJ, Wallace AM. Exaggerated adrenarche in a cohort of Scottish children: clinical features and biochemistry. *Clin Endocrinol* 2010;72:496-501
68. Liimatta J, Laakso S, Utriainen P, Voutilainen R, Palvimo JJ, Jaaskelainen T, Jaaskelainen J. Serum androgen bioactivity is low in children with PA. *Pediatr Res* 2014;75:645-650
69. Bizzarri C, Crea F, Marini R, Benevento D, Porzio O, Ravà L, Cappa M. Clinical features suggestive of non-classical 21-hydroxylase deficiency in children presenting with precocious pubarche. *J Pediatr Endocrinol Metab* 2012;25(11-12):1059-1064
70. Diaz A, Bhandari S, Sison C, Vogiatzi M. Characteristics of children with premature pubarche in the New York metropolitan area. *Horm Res* 2008;70:150-154
71. Gurnukar S, Arheart KL, Messiah SE, Mankodi A, Carillo A. Skeletal maturation and predicted adult height in children with PA. *J Pediatr Endocr Metab* 2014;27(1-2):69-74
72. Ibáñez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. *J Clin Endocrinol* 1998;83:3558-3562
73. Ibáñez L, DiMartino-Nardi J, Potau N, Sanger P. PA - normal variant or forerunner of adult disease? *Endocr Rev* 2000;21:671-696
74. DeSalvo DJ, Mehra R, Vaidyanathan P, Kaplowitz PB. In children with PA, bone age advancement by 2 or more years is common and generally benign. *J Pediatr Endocr Metab* 2013;26(3-4):215-221
75. Oron T, Leventhal Y, de Vries L, Yackobovitch-Gavan M, Phillip M, Lazar L. Interrelationship of extent of precocious adrenarche in appropriate for gestational age girls with clinical outcome. *J Pediatr* 2012;160(2):308-313
76. Klein KO, Newfield RS, Hassink SG. Bone maturation along the spectrum from normal weight to obesity: a complex interplay of sex, growth factors and weight gain. *J Pediatr Endocrinol Metab* 2016;29(3):311-318
77. Sopher AB, Jean AM, Zwany SK, Winston DM, Pomeranz CB, Bell JJ, McMahon DJ, Hasoun A, Fennoy I, Oberfield S. Bone age advancement in prepubertal children with obesity and PA: possible potentiating factors. *Obesity (Silver Spring)* 2011;19(6):1259-1264
78. Kwon JH, Lee HA, Kim YJ, Lee H, Park EA, Cho SJ, Gwak HS, Ha E, Park H, Kim HS. Effects of adrenal androgen levels on bone age advancement in prepubertal children: using the ewha birth and growth cohort study. *J Korean Med Sci* 2017;32(6):968-973
79. Pratt JH, Manatunga AK, Li W. Familial influences on the adrenal androgen excretion rate during the adrenarche. *Metabolism* 1994;43:186-189
80. Vottero A, Capelletti M, Giuliadori S, Viani I, Ziveri M, Neri TM, Bernasconi S, Ghizzoni L. Decreased androgen receptor gene methylation in premature pubarche: a novel pathogenetic mechanism? *J Clin Endocrinol Metab* 2006;91:968-972
81. Kang MJ, Lee JS, Kim HY, Jung HW, Lee YA, Lee SH, Seo JY, Kim JH, Chung HR, Kim SY, Shin CH, Yang SW. Contributions of CAG repeat length in the androgen receptor gene and androgen profiles to premature pubarche in Korean girls. *Endocr J* 2017;64(1):91-102
82. Lapalainen S, Utriainen P, Kuulasmaa T, Voutilainen R, Jaaskelainen J. ACTH receptor promoter polymorphism associates with severity of PA and modulates hypothalamo-pituitary-adrenal axis in children. *Pediatr Res* 2008;63:410-414
83. Petry CJ, Ong KK, Michelmore KF, Artigas S, Wingate DL, Balen AH, de Zegher F, Ibáñez L, Dunger DB. Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. *Hum Reprod* 2005;20:1837-1843
84. Witchel SF, Lee PA, Suda-Hartman M, Hoffman EP. Hyperandrogenism and manifesting heterozygotes for 21-hydroxylase deficiency. *Biochem Mol Med* 1997;62(2):151-158
85. Admoni O, Israel S, Lavi I, Gur M, Tenenbaum-Rakover Y. Hyperandrogenism in carriers of CYP21 mutations: the role of genotype. *Clin Endocrinol (Oxf)* 2006;64(6):645-651
86. Potau N, Riqué S, Eduardo I, Marcos V, Ibáñez L. Molecular defects of the CYP21 gene in Catalan girls with isolated precocious pubarche. *Eur J Endocrinol* 2002;147(4):485-488
87. Roldan MB, White C, Witchel SF. Association of the GAA1013-->GAG polymorphism of the insulin-like growth factor-1 receptor (IGF1R) gene with premature pubarche. *Fertil Steril* 2007;88(2):410-417
88. Utriainen P, Laakso S, Jääskeläinen J, Voutilainen R. Polymorphisms of POR, SULT2A1 and HSD11B1 in children with PA. *Metabolism* 2012;61(9):1215-1219
89. Ibáñez L, Potau N, Virdis R, Zampolli M, Terzi C, Gussinye M, Carrascosa A, Vicens-Calvet E. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. *J Clin Endocrinol Metab* 1993;76:1599-1603
90. Williams KM, Oberfield SE, Zhang C, McMahon DJ, Sopher A. The relationship of metabolic syndrome and body composition in children with PA: is age related? *Horm Res Pediatr* 2015;84(6):401-407
91. Rao JK, Chial HJ, Johnson CM. Primary polycystic ovary syndrome in a premenarcheal girl. A case report. *J Reprod Med* 1985;30:361-365
92. Bridges NA, Cooke A, Healy MJR, Hindmarsh PC, Brook CGD. Ovaries in sexual precocity. *Clin Endocrinol (Oxf)* 1995;42:135-140
93. Ibáñez L, Ong K, Dunger DB, de Zegher F. Early development of adiposity and insulin resistance after catch-up weight gain in small-for-gestational-age children. *J Clin Endocrinol Metab* 2006;91(6):2153-2158
94. Ibáñez L, Díaz R, López-Bermejo A, Marcos MV. Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism. *Eur Endocr Metab Disord* 2009;10(1):63-76
95. Ibáñez L, Castell C, Tresserras R, Potau N. Increased prevalence of unknown type 2 diabetes mellitus and impaired glucose tolerance in first-degree relatives of girls with a history of precocious pubarche. *Clin Endocrinol (Oxf)* 1999;51:395-401
96. Ibáñez L, Potau N, Zampolli M, Prat N, Virdis R, Vicens-Calvet E, Carrascosa A. Hyperinsulinemia in postpubertal girls with a history of premature pubarche and functional ovarian hyperandrogenism. *J Clin Endocrinol Metab* 1996;81:1237-1243
97. Ibáñez L, Ong KK, López-Bermejo A, Dunger DB, de Zegher F. Hyperinsulinaemic androgen excess in adolescent girls. *Nat Rev Endocrinol* 2014;10(8):499-508
98. Ibáñez L, Jaramillo A, Ferrer A, de Zegher F. High neutrophil count in girls and women with hyperinsulinemic hyperandrogenism: normalization with metformin and flutamide overcomes aggravation by oral contraception. *Hum Reprod* 2005;20:2457-2462
99. Ibáñez L, Ong K, de Zegher F, Marcos MV, del Rio L, Dunger DB. Fat distribution in non-obese girls with and without precocious pubarche: central adiposity related to insulinaemia and androgenaemia from prepuberty to postmenarche. *Clinical Endocrinology* 2003;58:372-379

100. Nordman H, Voutilainen R, Antikainen L, Jaaskelainen J. Prepubertal children born large for gestational age have lower serum DHEAS concentrations than those with a lower birth weight. *Pediatric Research* 2017;82(2):285-289
101. Fauser BCJM, Tarlatzis BC, Rebar R, Legro R, Balen A, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JSE, Bovin J, Petraglia F, Wijeyeratne CN, Norman R, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. *Fertil Steril* 2012;97:28-38
102. Orio F Jr, Paolumba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L, Nardo LG, Labella D, Savastano S, Russo T, Zullo F, Colao A, Lombardi G. The increase of leukocytes as a new putative marker of low grade chronic inflammation and early cardiovascular risk in the polycystic ovary syndrome. *J Clin Endocrinol Metab* 2005;90:2-5
103. Witchel SF. Puberty and polycystic ovary syndrome. *Mol Cell Endocrinol* 2006;254-255:146-153
104. Zhang L-H, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. *Proc Natl Acad Sci* 1995;92:10619-10623
105. Cara JF, Rosenfield RL. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. *Endocrinology* 1988;123(2):733-139
106. Duleba AJ, Spaczynski RZ, Olive DL. Insulin and insulin-like growth factor I stimulate the proliferation of human ovarian theca-interstitial cells. *Fert and Steril* 1998;69(2):335-340
107. Plymate SR, Hoop RC, Jones RE, Matej LA. Regulation of sex hormone-binding globulin production by growth factors. *Metabolism* 1990;39(9):967-970
108. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. *J Clin Endocrinol Metab* 1991;72(1):83-89
109. Aydın B, Winters SJ. Sex hormone-binding globulin in children and adolescents. *J Clin Res Pediatr Endocrinol* 2016;8(1):1-12
110. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. *Endocrinology* 2003;144(12):5159-5165
111. Higgins V, Adeli K. *Pediatric Metabolic Syndrome: Pathophysiology and Laboratory Assessment*. *EJIFCC* 2017;28(1):25-42
112. Ibáñez L, Oberfield SE, Witchel SF, Auchus RJ, Chang RJ, Codner E, Dabadghao P, Darendeliler F, Elbarbary NS, Gambineri A, Garcia Rudaz C, Hoeger KM, Lopez-Bermejo A, Ong K, Pena AS, Reinehr T, Santoro N, Tena-Sempere M, Tao R, Yildiz BO, Alkhayyat H, Deeb A, Dipesalema J, Horikawa R, de Zegher F, Lee PA. An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome (PCOS) in Adolescence. *Horm Res Pediatr* 2017; In Press: DOI:10.1149/000479371
113. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002;106(25):3143-421
114. Morrison JA, Friedman LA, Wang P, Glueck CJ. Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later. *J Pediatr* 2008;152(2):201-206
115. Devaraj S, Jialal I. The skinny on metabolic syndrome in adolescents. *Transl Pediatr* 2016;5(2):97-99
116. DeBoer MD, Gurka MJ. Clinical utility of metabolic syndrome severity scores: considerations for practitioners. *Diabetes Metab Syndr Obes* 2017;10:65-72
117. Idkowiak J, Lavery GG, Dhir V, Barrett TG, Stewart PM, Krone N, Arlt W. PA: novel lessons from early onset androgen excess. *Eur J Endocrinol* 2011;165(2):189-207
118. Meas T, Chevenne D, Thibaud E, Léger J, Cabrol S, Czernichow P, Lévy-Marchal C. Endocrine consequences of premature pubarche in post-pubertal Caucasian girls. *Clin Endocrinol (Oxf)* 2002;57(1):101-106
119. Sopher AB, Gerken AT, Lee E-J, Blaner WE, Deeds S, Gallagher D, Shungu DC, Mao X, Hassoun A, McMahon DJ, Oberfield SE. Retinol-binding protein 4 correlates with triglycerides but not insulin resistance in prepubertal children with and without PA. *J Pediatr Endocrinol Metab* 2011;2(0):683-687
120. Mantyselka A, Jaaskelainen J, Lindi V, Viitasalo A, Tompuri T, Voutilainen R, Lakka TA. The presentation of adrenarche is sexually dimorphic and modified by body adiposity. *J Clin Endocrinol Metab* 2014;99(10):3889-3894
121. Conley AJ, Plant TM, Abbott DH, Moeller BC, Stanley SD. Adrenal androgen concentrations increase during infancy in male rhesus macaques (*Macaca mulatta*). *Am J Physiol Endocrinol Metab* 2011;301(6):E1229-E1235
122. Nguyen AD, Mapes SM, Corbin CJ, Conley AJ. Morphological adrenarche in rhesus macaques: development of the zona reticularis is concurrent with fetal zone regression in the early neonatal period. *J Endocrinol* 2008;199:367-378
123. Campbell B. Adrenarche in comparative perspective. *Am J Hum Biol* 2011;23(1):44-52
124. Houghton LC, Cooper GD, Booth M, Chowdhury OA, Troisi R, Ziegler RG, Katki HA, Hoover RN, Bentley GR. Childhood environment influences adrenarcheal timing among first-generation Bangladeshi migrant girls to the UK. *PLoS One* 2014;9(10):e109200
125. Sontag-Padilla LM, Dorn LD, Tissot A, Susman EJ, Beers SR, Rose SR. Executive functioning, cortisol reactivity, and symptoms of psychopathology in girls with PA. *Dev Psychopathol* 2012;24(1):211-223
126. Dorn LD, Rose SR, Rotenstein D, Susman EJ, Huang B, Loucks TL, Berga SL. Differences in endocrine parameters and psychopathology in girls with PA versus on-time adrenarche. *J Pediatr Endocrinol Metab* 2008;21(5):439-448
127. Belsky J, Ruttle PL, Boyce WT, Armstrong JM, Essex MJ. Early adversity, elevated stress physiology, accelerated sexual maturation, and poor health in females. *Dev Psychol* 2015;51(6):816-822
128. Nguyen TV, McCracken JT, Ducharme S, Cropp BF, Botteron KN, Evans AC, Karama S. Interactive effects of dehydroepiandrosterone and testosterone on cortical thickness during early brain development. *J Neurosci* 2013;33(26):10840-10848
129. Murray CR, Simmons JG, Allen NB, Byrne ML, Mundy LK, Seal ML, Patton GC, Olsson CA, Whittle S. Associations between dehydroepiandrosterone (DHEA) levels, pituitary volume, and social anxiety in children. *Psychoneuroendocrinology* 2016;64:31-39
130. Goddings AL, Mills KL, Clasen LS, Giedd JN, Viner RM, Blakemore SJ. The influence of puberty on subcortical brain development. *Neuroimage* 2014;88:242-251
131. Byrne ML, Whittle S, Vijayakumar N, Dennison M, Simmons JG, Allen NB. A systematic review of adrenarche as a sensitive period in neurobiological development and mental health. *Dev Cogn Neurosci* 2017;25:12-28